Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 1, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 27, 2026Notice of sale · Form 144Bruce I. Sachs · Director · $662.5KOpen the filing ↗
- Aug 4, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record3,3779 flagged findings
Reported transactions (Form 4)80since Oct 15, 2024 · and 6 other holdings
Corporate events (8-K)30since May 18, 2018
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-05capital return (buybacks/dividends)recentOpen filing ↗“…As a result, using the multi period earnings method of the income approach, we recorded a full intangible asset impairment charge…”
+1 more passage from the same document
- “…and administrative expenses 61.5 63.4 Total stock-based compensation expense included in “Total costs and expenses” 166.4 166.1…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 3,377)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 10, 26Form 4 ↗Insider transaction
- Sep 10, 26Form 3 ↗Insider transaction
- Sep 1, 26Form 4 ↗Insider transaction
- Sep 1, 268-K ↗Current report · A senior executive left or was appointed
- Aug 31, 26Form 4 ↗Insider transaction
- Aug 27, 26Form 144 ↗Notice of proposed sale
- Aug 4, 2610-Q ↗Quarterly report
- Aug 3, 268-K ↗Current report · Results
- Jul 7, 268-K ↗Current report · Entered a material agreement
Notice of proposed sale · 3 Form 144 filingsshow all 3hide
- Jul 2, 26Form 144 ↗Notice of proposed sale
- Jul 2, 26Form 144 ↗Notice of proposed sale
- Jul 1, 26Form 144 ↗Notice of proposed sale
- Jun 30, 26Form 4 ↗Insider transaction
- Jun 26, 26Form 144 ↗Notice of proposed sale
- Jun 23, 26Form 4 ↗Insider transaction
- Jun 18, 26Form 144 ↗Notice of proposed sale
- Jun 17, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 144 ↗Notice of proposed sale
3,377 filings on record, the oldest from Feb 15, 95.
Listing the 25 most recent filings of the 3,377 on record.
79243
- Sep 1, 26A senior executive left or was appointed8-K 5.02 ↗
- Jul 7, 26Entered a material agreement+3 more in the same filing8-K 1.01 ↗
4 senior executive changes2025 – 2026show all 4hide
- May 13, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 29, 26A senior executive left or was appointed8-K 5.02 ↗
- Aug 4, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Feb 10, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Aug 16, 24Entered a material agreement8-K 1.01 ↗
- Apr 11, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Dec 5, 23A senior executive left or was appointed8-K 5.02 ↗
- Oct 5, 23A senior executive left or was appointed8-K 5.02 ↗
- Jul 5, 22A material agreement was terminated+2 more in the same filing8-K 1.02 ↗
- Apr 20, 21Entered a material agreement8-K 1.01 ↗
- Sep 21, 20Took on a new financial obligation+1 more in the same filing8-K 2.03 ↗
- Apr 1, 20A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 17, 19A debt obligation was accelerated+3 more in the same filing8-K 2.04 ↗
9 older filings not shown · The record reaches back to Sep 17, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Oct 25, 17Write-down of assets+3 more in the same filing8-K 2.06 ↗
- Oct 17, 16A debt obligation was accelerated+3 more in the same filing8-K 2.04 ↗
- Jan 29, 14Write-down of assets+3 more in the same filing8-K 2.06 ↗
- Oct 29, 13Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- May 17, 13A debt obligation was accelerated+2 more in the same filing8-K 2.04 ↗
- Feb 1, 07A debt obligation was accelerated+3 more in the same filing8-K 2.04 ↗
The full record holds 7 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Capital World Investors10.1%Mar 31, 26SCHEDULE 13G/A ↗1 earlier filing
- Capital Research Global Investors8.3%Mar 31, 26SCHEDULE 13G/A ↗2 earlier filings
- Vanguard Capital Management7.5%Mar 31, 26SCHEDULE 13G ↗
- FMR LLC3.6%Dec 31, 24SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 27, Bruce I. Sachs filed notice of intent to sell up to $663K.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
No sale of theirs is on record yet in Form 4; the 90-day window is still open.
View notice (Form 144) ↗+4 more recent notices · 4 with a later sale
- Jul 2, 26Sell$800KDuncan McKechnieEVP, Chief Commercial Officer↗
- Jul 2, 26Sell$787KOurania TatsisEVP, Chief Reg. & Quality Off.↗
- Jul 1, 26Sell$416KJoy LiuEVP and Chief Legal Officer↗
- Jun 26, 26Sell$288KCarmen BozicEVP and CMO↗
- Jun 18, 26Sell$471KCarmen BozicEVP and CMO↗
- Jun 15, 26Sell$1.8MCarmen BozicEVP and CMO↗
- Jun 5, 26Sell$785KCarmen BozicEVP and CMO↗
- Jun 1, 26Sell$364KJoy LiuEVP and Chief Legal Officer↗
- May 29, 26Sell$888KCarmen BozicEVP and CMO↗
- May 15, 26Sell$614KCarmen BozicEVP and CMO↗
- May 15, 26Sell$15KMark E. BunnageEVP, Chief Scientific Officer↗
- May 12, 26Sell$3.1MCarmen BozicEVP and CMO↗
There are 14 more transactions in this stretch.
Stock compensation, tax and giftsshow the 14 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 8, 26Compensationamount n/aGrunsven Jasper vanEVP, CP and NPPO↗
- Aug 28, 26Compensationamount n/aKristen AmbroseSVP & Chief Accounting Officer↗
- Aug 27, 26Giftamount n/aBRUCE I SACHS↗
- Jul 21, 26Compensationamount n/aAmit SachdevEVP Chief Patient & Ext Af Off↗
- Jul 21, 26Compensationamount n/aOurania TatsisEVP, Chief Reg. & Quality Off.↗
- May 1, 26Compensationamount n/aSangeeta N. Bhatia↗
- May 1, 26Compensationamount n/aAlan M Garber↗
- May 1, 26Compensationamount n/aDIANA MCKENZIE↗
- May 1, 26Otheramount n/aDIANA MCKENZIE↗
- May 1, 26Compensationamount n/aJennifer Schneider↗
- May 1, 26Otheramount n/aJennifer Schneider↗
- May 1, 26Compensationamount n/aNancy Thornberry↗
- May 1, 26Otheramount n/aNancy Thornberry↗
- May 1, 26Otheramount n/aSuketu Upadhyay↗
The full record holds 727 transactions and goes back to May 17, 22.
Its sector and its market
Vertex Pharmaceuticals Incorporated among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Vertex Pharmaceuticals Incorporated, the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Vertex Pharmaceuticals Incorporated in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 3,377 documents on file, from Feb 15, 1995 to Sep 10, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.